Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 167 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2014', provides an overview of the Keratoconjunctivitis sicca (Dry Eye)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Keratoconjunctivitis sicca (Dry Eye) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Keratoconjunctivitis sicca (Dry Eye) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Keratoconjunctivitis sicca (Dry Eye) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Keratoconjunctivitis sicca (Dry Eye) Overview 8
Therapeutics Development 9
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 9
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis 10
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 11
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 19
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 22
Allergan, Inc. 22
Seikagaku Corporation 23
Merck & Co., Inc. 24
Santen Pharmaceutical Co., Ltd. 25
EyeGate Pharmaceuticals, Inc. 26
Kissei Pharmaceutical Co., Ltd. 27
Shire Plc 28
InSite Vision Incorporated 29
NovaBay Pharmaceuticals, Inc. 30
Circadian Technologies Limited 31
RegeneRx Biopharmaceuticals, Inc. 32
HanAll Biopharma Co., Ltd. 33
Huons Co., Ltd. 34
R-Tech Ueno, Ltd. 35
Digna Biotech, S.L. 36
Scynexis, Inc. 37
Lipicard Technologies Limited 38
Parion Sciences, Inc. 39
Novaliq GmbH 40
Xigen SA 41
Kainos Medicine, Inc. 42
PharmaNova Inc. 43
Resolvyx Pharmaceuticals, Inc 44
Winston Pharmaceuticals, Inc. 45
SIFI S.p.A 46
Celsus Therapeutics Plc 47
Dompe Farmaceutici S.p.A. 48
Mimetogen Pharmaceuticals Inc. 49
Kala Pharmaceuticals, Inc. 50
Otsuka Holdings Co., Ltd. 51
Laboratorios Sophia S.A. de C.V. 52
Eleven Biotherapeutics 53
Herantis Pharma plc. 54
Neuroptis Biotech 55
OncoNOx ApS 56
Dong-A Socio Group 57
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Target 59
Assessment by Mechanism of Action 63
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
diquafosol tetrasodium - Drug Profile 71
cyclosporine - Drug Profile 73
rebamipide - Drug Profile 76
lifitegrast - Drug Profile 78
dexamethasone acetate - Drug Profile 80
MIMD-3 - Drug Profile 82
PRO-148 - Drug Profile 83
EBI-005 - Drug Profile 85
SI-614 - Drug Profile 86
cyclosporine - Drug Profile 87
P-321 - Drug Profile 88
RGN-259 - Drug Profile 89
zucapsaicin - Drug Profile 91
RU-101 - Drug Profile 93
recoflavone - Drug Profile 94
ISV-101 - Drug Profile 96
ozagrel - Drug Profile 97
Recombinant Human Nerve Growth Factor - Drug Profile 98
loteprednol etabonate - Drug Profile 99
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 100
XG-104 - Drug Profile 102
KL-7016 - Drug Profile 103
Small Molecule for Immunology, Ophthalmology, Oncology and Dermatology - Drug Profile 104
cyclosporine - Drug Profile 106
cyclosporine - Drug Profile 107
P-17 - Drug Profile 108
disitertide - Drug Profile 110
RX-20001 - Drug Profile 112
SF-104 - Drug Profile 113
VGX-100 - Drug Profile 114
HL-036 - Drug Profile 116
KeraKlear - Drug Profile 117
OPX-1 - Drug Profile 118
SCY-641 - Drug Profile 119
NVC-727 - Drug Profile 120
NVC-638 - Drug Profile 121
NVC-704 - Drug Profile 122
NOP-3 - Drug Profile 123
NOP-5 - Drug Profile 124
PN-202 - Drug Profile 125
OX-1001 - Drug Profile 126
P-1037 - Drug Profile 127
Lacritin - Drug Profile 128
KBP-7306 - Drug Profile 129
KM-401 - Drug Profile 130
cyclosporine Nanoemulsion - Drug Profile 131
Keratoconjunctivitis sicca (Dry Eye) - Recent Pipeline Updates 132
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 152
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 153
Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 154
Featured News & Press Releases 154
Appendix 163
Methodology 163
Coverage 163
Secondary Research 163
Primary Research 163
Expert Panel Validation 163
Contact Us 164
Disclaimer 164

List of Tables
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2014 12
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Development by Companies, H2 2014 (Contd..2) 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Comparative Analysis by Unknown Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Development by Companies, H2 2014 (Contd..2) 24
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan, Inc., H2 2014 25
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H2 2014 26
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H2 2014 27
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 28
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2014 29
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 30
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H2 2014 31
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H2 2014 32
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2014 33
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Circadian Technologies Limited, H2 2014 34
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 35
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 36
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H2 2014 37
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by R-Tech Ueno, Ltd., H2 2014 38
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H2 2014 39
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Scynexis, Inc., H2 2014 40
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H2 2014 41
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H2 2014 42
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2014 43
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2014 44
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kainos Medicine, Inc., H2 2014 45
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by PharmaNova Inc., H2 2014 46
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Resolvyx Pharmaceuticals, Inc, H2 2014 47
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Winston Pharmaceuticals, Inc., H2 2014 48
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by SIFI S.p.A, H2 2014 49
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Celsus Therapeutics Plc, H2 2014 50
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 51
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2014 52
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 53
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 54
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2014 55
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Eleven Biotherapeutics, H2 2014 56
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma plc., H2 2014 57
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H2 2014 58
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2014 59
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dong-A Socio Group, H2 2014 60
Assessment by Monotherapy Products, H2 2014 61
Number of Products by Stage and Target, H2 2014 64
Number of Products by Stage and Mechanism of Action, H2 2014 68
Number of Products by Stage and Route of Administration, H2 2014 71
Number of Products by Stage and Molecule Type, H2 2014 73
Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Recent Pipeline Updates, H2 2014 135
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2014 155
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2014 156